Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients
Authors:
- 16 January 2026
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (6) , 1015-1026
Abstract
Background: Limited research exists on immune checkpoint inhibitors (ICIs)' antiviral efficacy in hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC). This study aimed to evaluate the impact of ICIs on multiple HBV markers and its correlation with HCC prognosis. Methods: A retrospective cohort study was performed on 318 HBV-related HCC patients, including 268 who received ICIs (with/without targeted therapy; ICI group) and 50 who received targeted therapy alone (non-ICI group). Levels of quantitative HBsAg (qHBsAg), HBV DNA, HBV RNA, and HBcrAg were monitored. Tumor response was evaluated using RECIST 1.1. Results: Over a median 8.1-month follow-up, the ICI group showed a significantly greater decrease in all HBV markers. At week 96, the ICI group showed significantly higher cumulative incidences of HBsAg response (loss or ≥0.5 Log10 decline) (41.6% vs 14.9%, P = .006) and HBcrAg response (negativity or ≥1 Log10 decline) (46.3% vs 18.1%, P = .007) than non-ICI group and a significantly faster achievement rate of HBV RNA response (negativity or ≥0.5 Log10 decline) (hazard ratio [HR]: 1.80, 95% CI: 1.08–2.99, P = .021). Notably, the PD-1 inhibitors showed significantly better virological response efficacy than PD-L1 inhibitors (HR = 2.04–5.43). The patients with lower levels of HBV markers at enrollment demonstrated significantly better overall survival. Moreover, patients achieving virological response were associated with significantly better survival outcomes and tumor response, with HR ranging 1.64–8.06. Conclusions: Immune checkpoint inhibitors demonstrate dual therapeutic effects in HBV-related HCC, significantly reducing multiple HBV markers while concurrently enhancing prognosis in combination with antiviral therapy, emphasizing the importance of sustained virological suppression for optimal HCC outcomes.Keywords
Funding Information
- Nanfang Hospital
- Southern Medical University (2022J002)
This publication has 26 references indexed in Scilit:
- Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis BClinical Gastroenterology and Hepatology, 2024
- JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2Journal of Hepatology, 2024
- Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapyCancer Immunology, Immunotherapy, 2022
- Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCVClinical Gastroenterology and Hepatology, 2022
- Global, regional and national burden of primary liver cancer by subtypeEuropean Journal of Cancer, 2022
- Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot studyJournal of Hepatology, 2019
- Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic DeterminantHepatology, 2017
- Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and reboundJournal of Hepatology, 2016
- Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiationJournal of Hepatology, 2014
- A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis BJournal of Clinical Virology, 2011